Background and objective: Major risk factors for congestive heart failure (CHF) are myocardial infarction, hypertension, diabetes, atrial fibrillation, smoking, left ventricular hypertrophy (LVH) and obesity. However, since these risk factors only explain part of the risk of CHF, we investigated whether persistent organic pollutants (POPs) might also play a role. Methods: In the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study, left ventricular ejection fraction, (EF), E/A-ratio and isovolumic relaxation time (IVRT), were determined by echocardiography and serum samples of 21 POPs were analyzed in serum measured by high-resolution chromatography coupled to high-resolution mass spectrometry (HRGC/HRMS) in 998 subjects all aged 70 years. Results: In this cross-sectional analysis, high levels of several of the polychlorinated biphenyls (PCB congeners 99, 118, 105, 138, 153, and 180) and octachlorodibenzo-p-dioxin (OCDD) were significantly related to a decreased EF. Some POPs were also related to a decreased E/A-ratio (PCBs 206 and 209). All the results were adjusted for gender, hypertension, diabetes, smoking, LVH and BMI, and subjects with myocardial infarction or atrial fibrillation were excluded from the analysis. Conclusions: Circulating levels of POPs were related to impairments in both left ventricular systolic and diastolic function independently of major congestive heart failure risk factors, suggesting a possible role of POPs in heart failure.

名古屋大学博士学位論文 学位の種類 : 博士(医学)(論文) 学位授与年月日:平成5年2月19日 竹中晃氏の博士論文として提出された

Submitted by Bruno Cristian Rodrigues (bcr.bruno@hotmail.com) on 2018-05-24T17:50:20Z No. of bitstreams: 1 Dissertação Versão Final.pdf: 1282289 bytes, checksum: 220b5b70a270e2a384dab8b94d207bdc (MD5) / Approved for entry into archive by Alexandra Maria Donadon Lusser Segali null (alexmar@fcav.unesp.br) on 2018-05-28T13:42:27Z (GMT) No. of bitstreams: 1 rodrigues_bc_me_jabo.pdf: 1282289 bytes, checksum: 220b5b70a270e2a384dab8b94d207bdc (MD5) / Made available in DSpace on 2018-05-28T13:42:27Z (GMT). No. of bitstreams: 1 rodrigues_bc_me_jabo.pdf: 1282289 bytes, checksum: 220b5b70a270e2a384dab8b94d207bdc (MD5) Previous issue date: 2018-04-12 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / A degeneração mixomatosa da válvula mitral (DMVM) é a enfermidade mais comum na clínica de pequenos animais no âmbito das cardiopatias, cuja evolução pode resultar em alterações hemodinâmicas importantes decorrentes dos mecanismos neuro-hormonais compensatórios. Embora seu diagnóstico seja relativamente simples, as alterações intrínsecas podem ser subestimadas pelos exames convencionais, a exemplo da disfunção sistólica e reserva miocárdica que podem passar despercebidas à ecocardiografia. Desta forma, o objetivo do presente estudo foi avaliar a ocorrência de disfunção sistólica em cães com DMVM por meio do teste de estresse farmacológico com dobutamina. Para tanto, foram utilizados três grupos de cães: G1 (n=8) grupo controle, G2 (n=7) animais com DMVM e diâmetro interno do ventrículo esquerdo em diástole indexado à aorta (DIVEd/Ao) < 2,37 e G3 (n=6) animais com DMVM e DIVEd/Ao ≥ 2,37 em um total de 21 animais. O ecocardiograma foi realizado antes (T0) e após (T1) infusão contínua com dobutamina, que foi realizada da seguinte forma: 5μg/kg/minuto por cinco minutos e 10μg/kg/minuto durante 10 minutos (T1). Os resultados foram avaliados pelo teste de Tukey com nível de significância de 5% quanto às variáveis fração de ejeção (FEJ%) (variação percentual média (VPM) de FEJ% antes e após a infusão de dobutamina), VPM de fração de encurtamento (FEC%) e diâmetros internos do ventrículo esquerdo em sístole e diástole indexados pelo diâmetro da aorta (DIVEs/Ao e DIVEd/Ao). Os resultados acerca da VPM FEC% e VPM FEJ%,demonstraram que houve diferença estatística quanto à primeira variável entre os grupos G1 com G3, bem como entre G2 e G3, enquanto em relação à segunda, apenas o G1 e G3 diferiram estatisticamente. Por outro lado não houve diferença significativa (p>0,05) para as médias obtidas pré e pós dobutamina da FEC% e FEJ% entre todos os grupos, no entanto, houve diferença significativa dentro os grupos G1 e G2 quando analisados os momentos T0 e T1. Outrossim, verificando as médias obtidas do DIVEd/Ao, conclui-se que houve diferença entre os grupos G1 e G3 como também entre G2 e G3 (p<0,05). Por sua vez, as médias obtidas do DIVEs/Ao diferiram significativamente (p<0,05) em todos os grupos pré (T0) e pós dobutamina (T1), exceto no G3. Entre os grupos, as médias no T0, têm diferença estatística significante entre os grupos G1 e G3 (p<0,05). Ademais, Em relação ao VVEs/m², dentro dos grupos houve diferença significativa apenas entre G1 e G3. Já entre os tempos, apenas o G1 houve diferença entre T0 e T1. Por fim, constatou-se significância estatística (p<0,05) quando se correlacionou DIVEd/Ao com a VPM FEC% e VPM FEJ%, demonstrando que quanto maior o DIVEd/Ao menores são estas variáveis. Desta forma, conclui-se que a dobutamina é capaz de evidenciar disfunção sistólica em animais com DMVM, principalmente naqueles que têm um remodelamento maior (G3), sendo capaz de inferir uma forte relação entre o tamanho do DIVEd/Ao e disfunção sistólica. Além disso, notou -se que em animais com menor remodelamento do ventrículo esquerdo (VE), como os do grupo G2, a resposta inotrópica ao desafio farmacológico foi satisfatória, revelando a presença de reserva contrátil nestes pacientes. Por fim, o teste de estresse com dobutamina mostrou-se eficaz, seguro e aplicável na rotina clínica. / Myxomatous mitral valve disease (MMVD) is the most common cardiopathy in small animals, which evolution may result in important hemodynamic changes due to compensatory neurohormonal mechanisms. Although its diagnosis is relatively simple, intrinsic changes may be underestimated by conventional exams, as systolic dysfunction and myocardial reserve that may go unnoticed by echocardiograph. Therefore, the objective of the present study was to evaluate the occurrence of systolic dysfunction in dogs with MMVD through pharmacological stress test with dobutamine. The dogs were distributed in three groups: G1 (n = 8) control group, G2 (n = 7) animals with MMVD and left ventricular diastolic diameter indexed to the aorta (LVIDd:Ao) < 2.37 and G3 (n = 6) animals with MMVD and LVIDd:Ao ≥ 2.37. The echocardiograph was performed before (T0) and after (T1) continuous infusion of dobutamine, as follows: 5μg/kg/minute for five minutes and 10μg/kg/minute for 10 minutes (T1). The results were evaluated by Tukey test with significance level of 5% for the following variables: ejection fraction (EF%) (mean percentage variation (MPV) of EF% before and after dobutamine infusion), MPV of shortening fraction FS% and internal diameters of left ventricle in systole and in diastole indexed by aortic diameter (LVIDs:Ao and LVIDd:Ao). The results about the MPV FS% and the MPV EF% showed that there was statistical difference between the G1 and G3 groups, as well as between G2 and G3, while the G1 and G3 differed statistically from the G1 and G3 groups. On the other hand, there was no significant difference (p> 0.05) for the averages obtained before and after dobutamine of the FS% and EF% among all groups, however, there was a significant difference between groups G1 and G2 when the T0 moments and T1. In addition, it was concluded that there were differences between the G1 and G3 groups as well as between G2 and G3 (p <0.05). Also, by means of the LVIDd:Ao means, it was concluded that there was a difference between the G1 and G3 groups as well as between G2 and G3 (p <0.05). In it’s turn, the means obtained from LVIDs:Ao differed significantly (p <0.05) in all groups before (T0) and post-dobutamine (T1), except in G3. Among the groups, the averages at T0, have significant statistical difference between the G1 and G3 groups (p <0.05). In addition, with respect to ESV/m², within the groups there was a significant difference only between G1 and G3. Among the times, only G1 showed differences between T0 and T1. Finally, statistical significance (p <0.05) was found when DIVEd / Ao correlated with MPV FS% and EF%, demonstrating that the higher the LVIDd:Ao the lower these variables. Therefore, it was determined that dobutamine can point to systolic dysfunction in animals with MMVD, especially those showing greater remodeling (G3), also inferring a strong relationship between LVIDd:Ao size and systolic dysfunction. Furthermore, in animals with less left ventricular (LV) remodeling, such as those in group G2, inotropic response to pharmacological challenge was satisfactory, revealing the presence of contractile reserve in these patients. To conclude, dobutamine stress test showed effective, safe and applicable in clinical routine.

Objetivos: Determinar a prevalência de disfunção sistólica assintomática do ventrículo esquerdo no puerpério e comparar sua evolução com os casos de miocardiopatia periparto ocorridos no mesmo período. Pacientes e Métodos: Estudo transversal entre setembro de 2002 e abril de 2005, para determinar a prevalência de disfunção ventricular assintomática no puerpério imediato e a incidência de miocardiopatia periparto no mesmo período, e entre novembro de 2007 e janeiro de 2008 para verificar a evolução clínica e ecocardiográfica destas pacientes. Os parâmetros ecocardiográficos das puérperas com disfunção ventricular assintomática também foram comparados com os de puérperas normais. Disfunção sistólica do ventrículo esquerdo foi definida como diâmetro diastólico final ≥ 5,6 cm e/ou fração de ejeção < 53,0% + encurtamento fracional sistólico < 25%. Resultados: Foram rastreadas 1182 puérperas, sendo detectados 10 casos (0,85%) de disfunção ventricular assintomática, cujas características clínicas, como raça, superfície corporal, paridade, gemelaridade e uso de tocolíticos, não foram diferentes quando comparadas com 18 controles rastreados sem disfunção. A incidência de miocardiopatia periparto no período foi de 6 casos em 10866 partos (1/1811 partos de nascidos vivos). Após uma média de 4,0 anos (2,9-5,2 anos), 7 dos 10 casos de disfunção assintomática e 5 dos 6 casos de miocardiopatia clínica realizaram nova ecocardiografia, verificando-se significativo aumento da fração de ejeção e do encurtamento fracional médios nos dois grupos, sendo que a parcela de recuperação da função foi semelhante nos grupos (p interação > 0,05). Conclusões: Ocorre disfunção ventricular no puerpério sem os achados clínicos de insuficiência cardíaca cujos parâmetros ecocardiográficos evoluem de maneira semelhante aqueles de pacientes com miocardiopatia periparto ao longo do tempo. / Objective: To determine the prevalence of asymptomatic left ventricular systolic dysfunction in puerperium and to compare its progression with that of cases of peripartum cardiomyopathy that occurred in the same study period. Patients and Methods: Cross-sectional study conducted from September 2002 to April 2005 to determine the prevalence of asymptomatic ventricular dysfunction in early puerperium and the incidence of peripartum myocardiopathy, and from November 2007 to January 2008 to obtain clinical and echocardiographic follow-up data of the study patients. Echocardiographic parameters of puerperal women with asymptomatic ventricular dysfunction were also compared with those of normal puerperal women. The parameters to define left ventricular systolic dysfunction were end-diastolic diameter ≥ 5.6 cm and/or ejection fraction < 53.0%, and systolic fractional shortening < 25%. Results: A total of 1182 puerperal women were screened, and 10 cases (0.85%) of asymptomatic ventricular dysfunction were detected. Clinical characteristics, such as ethnicity, body surface, parity, multiple gestations, and tocolytic therapy, were not different from those of the 18 normal women used as controls. The incidence of peripartum cardiomyopathy was 6 cases out of 10866 deliveries (1/1811 live births). After a mean of 4.0 years (2.9-5.2 years), 7 of the 10 patients with asymptomatic dysfunction and 5 of the 6 with clinical cardiomyopathy underwent follow-up echocardiography. A significant increase was found in mean ejection fraction and fractional shortening in the two groups, and function recovery rates were similar in the two groups (p > 0.05). Conclusions: Ventricular dysfunction may occur in the puerperium without clinical signs of heart failure, and the long-term progression of echocardiographic parameters is similar to that found in cases of peripartum cardiomyopathy.

Objetivos: Determinar a prevalência de disfunção sistólica assintomática do ventrículo esquerdo no puerpério e comparar sua evolução com os casos de miocardiopatia periparto ocorridos no mesmo período. Pacientes e Métodos: Estudo transversal entre setembro de 2002 e abril de 2005, para determinar a prevalência de disfunção ventricular assintomática no puerpério imediato e a incidência de miocardiopatia periparto no mesmo período, e entre novembro de 2007 e janeiro de 2008 para verificar a evolução clínica e ecocardiográfica destas pacientes. Os parâmetros ecocardiográficos das puérperas com disfunção ventricular assintomática também foram comparados com os de puérperas normais. Disfunção sistólica do ventrículo esquerdo foi definida como diâmetro diastólico final ≥ 5,6 cm e/ou fração de ejeção < 53,0% + encurtamento fracional sistólico < 25%. Resultados: Foram rastreadas 1182 puérperas, sendo detectados 10 casos (0,85%) de disfunção ventricular assintomática, cujas características clínicas, como raça, superfície corporal, paridade, gemelaridade e uso de tocolíticos, não foram diferentes quando comparadas com 18 controles rastreados sem disfunção. A incidência de miocardiopatia periparto no período foi de 6 casos em 10866 partos (1/1811 partos de nascidos vivos). Após uma média de 4,0 anos (2,9-5,2 anos), 7 dos 10 casos de disfunção assintomática e 5 dos 6 casos de miocardiopatia clínica realizaram nova ecocardiografia, verificando-se significativo aumento da fração de ejeção e do encurtamento fracional médios nos dois grupos, sendo que a parcela de recuperação da função foi semelhante nos grupos (p interação > 0,05). Conclusões: Ocorre disfunção ventricular no puerpério sem os achados clínicos de insuficiência cardíaca cujos parâmetros ecocardiográficos evoluem de maneira semelhante aqueles de pacientes com miocardiopatia periparto ao longo do tempo. / Objective: To determine the prevalence of asymptomatic left ventricular systolic dysfunction in puerperium and to compare its progression with that of cases of peripartum cardiomyopathy that occurred in the same study period. Patients and Methods: Cross-sectional study conducted from September 2002 to April 2005 to determine the prevalence of asymptomatic ventricular dysfunction in early puerperium and the incidence of peripartum myocardiopathy, and from November 2007 to January 2008 to obtain clinical and echocardiographic follow-up data of the study patients. Echocardiographic parameters of puerperal women with asymptomatic ventricular dysfunction were also compared with those of normal puerperal women. The parameters to define left ventricular systolic dysfunction were end-diastolic diameter ≥ 5.6 cm and/or ejection fraction < 53.0%, and systolic fractional shortening < 25%. Results: A total of 1182 puerperal women were screened, and 10 cases (0.85%) of asymptomatic ventricular dysfunction were detected. Clinical characteristics, such as ethnicity, body surface, parity, multiple gestations, and tocolytic therapy, were not different from those of the 18 normal women used as controls. The incidence of peripartum cardiomyopathy was 6 cases out of 10866 deliveries (1/1811 live births). After a mean of 4.0 years (2.9-5.2 years), 7 of the 10 patients with asymptomatic dysfunction and 5 of the 6 with clinical cardiomyopathy underwent follow-up echocardiography. A significant increase was found in mean ejection fraction and fractional shortening in the two groups, and function recovery rates were similar in the two groups (p > 0.05). Conclusions: Ventricular dysfunction may occur in the puerperium without clinical signs of heart failure, and the long-term progression of echocardiographic parameters is similar to that found in cases of peripartum cardiomyopathy.

Objetivos: Determinar a prevalência de disfunção sistólica assintomática do ventrículo esquerdo no puerpério e comparar sua evolução com os casos de miocardiopatia periparto ocorridos no mesmo período. Pacientes e Métodos: Estudo transversal entre setembro de 2002 e abril de 2005, para determinar a prevalência de disfunção ventricular assintomática no puerpério imediato e a incidência de miocardiopatia periparto no mesmo período, e entre novembro de 2007 e janeiro de 2008 para verificar a evolução clínica e ecocardiográfica destas pacientes. Os parâmetros ecocardiográficos das puérperas com disfunção ventricular assintomática também foram comparados com os de puérperas normais. Disfunção sistólica do ventrículo esquerdo foi definida como diâmetro diastólico final ≥ 5,6 cm e/ou fração de ejeção < 53,0% + encurtamento fracional sistólico < 25%. Resultados: Foram rastreadas 1182 puérperas, sendo detectados 10 casos (0,85%) de disfunção ventricular assintomática, cujas características clínicas, como raça, superfície corporal, paridade, gemelaridade e uso de tocolíticos, não foram diferentes quando comparadas com 18 controles rastreados sem disfunção. A incidência de miocardiopatia periparto no período foi de 6 casos em 10866 partos (1/1811 partos de nascidos vivos). Após uma média de 4,0 anos (2,9-5,2 anos), 7 dos 10 casos de disfunção assintomática e 5 dos 6 casos de miocardiopatia clínica realizaram nova ecocardiografia, verificando-se significativo aumento da fração de ejeção e do encurtamento fracional médios nos dois grupos, sendo que a parcela de recuperação da função foi semelhante nos grupos (p interação > 0,05). Conclusões: Ocorre disfunção ventricular no puerpério sem os achados clínicos de insuficiência cardíaca cujos parâmetros ecocardiográficos evoluem de maneira semelhante aqueles de pacientes com miocardiopatia periparto ao longo do tempo. / Objective: To determine the prevalence of asymptomatic left ventricular systolic dysfunction in puerperium and to compare its progression with that of cases of peripartum cardiomyopathy that occurred in the same study period. Patients and Methods: Cross-sectional study conducted from September 2002 to April 2005 to determine the prevalence of asymptomatic ventricular dysfunction in early puerperium and the incidence of peripartum myocardiopathy, and from November 2007 to January 2008 to obtain clinical and echocardiographic follow-up data of the study patients. Echocardiographic parameters of puerperal women with asymptomatic ventricular dysfunction were also compared with those of normal puerperal women. The parameters to define left ventricular systolic dysfunction were end-diastolic diameter ≥ 5.6 cm and/or ejection fraction < 53.0%, and systolic fractional shortening < 25%. Results: A total of 1182 puerperal women were screened, and 10 cases (0.85%) of asymptomatic ventricular dysfunction were detected. Clinical characteristics, such as ethnicity, body surface, parity, multiple gestations, and tocolytic therapy, were not different from those of the 18 normal women used as controls. The incidence of peripartum cardiomyopathy was 6 cases out of 10866 deliveries (1/1811 live births). After a mean of 4.0 years (2.9-5.2 years), 7 of the 10 patients with asymptomatic dysfunction and 5 of the 6 with clinical cardiomyopathy underwent follow-up echocardiography. A significant increase was found in mean ejection fraction and fractional shortening in the two groups, and function recovery rates were similar in the two groups (p > 0.05). Conclusions: Ventricular dysfunction may occur in the puerperium without clinical signs of heart failure, and the long-term progression of echocardiographic parameters is similar to that found in cases of peripartum cardiomyopathy.

Résumé: Mise en contexte : Les infarctus antérieurs avec élévation du segment ST (IMAEST) causent fréquemment une dysfonction ventriculaire gauche. Une diminution de la fraction d’éjection du ventricule gauche (FeVG) est associée à une augmentation du risque d’accident vasculaire cérébral (AVC). Les lignes directrices recommandaient jusqu’à récemment (Classe I, niveau d’évidence C) l’anticoagulation des patients qui, après un IMAEST, étaient jugés à haut risque d’embolie systémique tels que les infarctus étendus ou de la paroi antérieure. Généralement, ces patients reçoivent une anticoagulation d’une durée de trois mois en combinaison avec une double thérapie antiplaquettaire pour au moins quatre semaines. Si les anomalies régionales de la contractilité se normalisaient avant trois mois, la durée de l’anticoagulation pourrait potentiellement être écourtée. La cinétique de récupération des infarctus antérieurs revascularisés par angioplastie primaire est mal décrite. Objectif : Chez des patients ayant subi un IMAEST de la paroi antérieure revascularisés par angioplastie primaire, évaluer si la FeVG et la récupération de l’akinésie antérieure et apicale est différente à un mois et trois mois post infarctus. Méthode : De façon prospective, nous avons recruté 42 patients présentant une FEVG de 45% ou moins et une akinésie de la paroi antérieure ou apicale lors de l’échocardiographie réalisée 48 heures post IMAEST. Des échocardiographies étaient obtenues à un mois et trois mois post IMAEST. Chaque échocardiographie était interprétée par deux cardiologues indépendants à l’aveugle des données cliniques. Résultats : Lorsque comparée à la FeVG à 48 heures post IMAEST, la FeVG à un mois s’était déjà améliorée de façon significative (38% à 42%, p=0.03). Il n’y avait pas d’amélioration significative supplémentaire entre un mois et trois mois (42% à 44%, p=NS). La dynamique des segments apicaux et antérieurs s’améliorait de façon significative entre 48 heures et un mois, mais aussi entre un mois et trois mois. Conclusion : Vu l’amélioration significative de la FeVG et de l’akinésie antérieure et apicale à un mois post IMAEST, il pourrait être justifié de ré-évaluer la FeVG plus précocement chez les patients anticoagulés pour cette indication afin de minimiser la durée de l’anticoagulation et le risque de saignement qui y est associé. / Abstract: Background: Anterior ST-elevation myocardial infarction (STEMI) frequently causes left ventricular dysfunction. Worsening left ventricular ejection fraction (LVEF) is associated a higher stroke rate. Prior guidelines recommended anticoagulation for patients after STEMI who are at high risk for systemic emboli and specified that large or anterior myocardial infarctions (MI) are part of that group (Class I, level of Evidence C). The 2013 Guidelines made it a Class IIB recommendation and restricted the recommendation to those with anterior or apical akinesia and dyskinesia. These patients are usually given three months of anticoagulation. If the regional wall motion abnormalities were to normalize earlier, the duration of anticoagulation could be shortened. However, the kinetics of recovery after an anterior MI revascularized with primary percutaneous intervention are not well described. Objective: To evaluate if LVEF and apical and anterior akinesia recuperation is different at one month and three months after STEMI in patients treated with primary percutaneous angioplasty. Methods: We prospectively recruited 42 patients who had a LVEF of 45% or less and apical or anterior akinesia on echocardiography at 48 hours post STEMI. Echocardiography was repeated one month and three months post STEMI. Each echocardiogram was interpreted by two different cardiologists who were blinded to clinical information. Results: When compared to 48 hours post STEMI, LVEF at one month had already improved significantly (38% to 42%, p=0.03) and there was no further significant improvement at three months (44%, p=NS). Anterior and apical akinesia decreased significantly between the 48 hours and one month echocardiograms, but also between one month and three months. Conclusion: Given that LVEF and anterior/apical akinesia improve significantly within the first post STEMI month, it may be worth re-evaluating the LVEF earlier in patients in whom the decision was made to start anticoagulation for that indication in order to minimize the duration of anti-coagulation and the associated bleeding risk.

No description available.